CAMBRIDGE, MA – December 1, 2018 – X4 Pharmaceuticals, a
Mirati Presents Data From Ongoing Phase 2 Clinical Trial Of Mocetinostat In Combination With Durvalumab At The SITC 33rd Annual Meeting
SAN DIEGO, Nov. 9, 2018 /PRNewswire/ — Mirati Therapeutics, Inc.